Correlation of bivalirudin dose with creatinine clearance during treatment of heparin-induced thrombocytopenia.
Aged, Aged, 80 and over, Antithrombins, Creatinine, Dose-Response Relationship, Drug, Female, Heparin, Hirudins, Humans, Infusions, Intravenous, International Normalized Ratio, Male, Middle Aged, Partial Thromboplastin Time, Peptide Fragments, Recombinant Proteins, Renal Replacement Therapy, Retrospective Studies, Thrombocytopenia
STUDY OBJECTIVES: To evaluate steady-state bivalirudin dosing requirements in patients with a wide range of kidney function who were being treated for heparin-induced thrombocytopenia (HIT)-related disorders.
DESIGN: Retrospective medical record review.
SETTING: Academic medical center.
PATIENTS: Sixty-four adults with varying degrees of renal function who were receiving bivalirudin for at least 48 hours for HIT-related disorders between March 2007 and May 2010.
MEASUREMENTS AND MAIN RESULTS: Steady-state conditions were defined as a constant bivalirudin infusion dose for at least 12 hours, with serum creatinine concentration varying less than 20% for 48 hours (for patients not receiving renal replacement therapy) and at least two therapeutic activated partial thromboplastin time (aPTT) values (60-80 sec). Patients were assigned to five groups based on Cockcroft-Gault-estimated creatinine clearance (Clcr) of less than 30, 30-60, or greater than 60 ml/minute, or by type of renal replacement therapy-intermittent hemodialysis or continuous venovenous hemofiltration (CVVH). For Clcr greater than 60 ml/minute, the median bivalirudin dose was 0.15 mg/kg/hour (interquartile range [IQR] 0.11-0.15 mg/kg/hr), which was greater than median doses for Clcr 30-60 ml/minute (0.10 mg/kg/hr, IQR 0.06-0.13 mg/kg/hr, p=0.004), Clcr less than 30 ml/minute (0.08 mg/kg/hr, IQR 0.04-0.1 mg/kg/hr, p=0.001), CVVH (0.06 mg/kg/hr, IQR 0.03-0.10 mg/kg/hr, p=0.046), and hemodialysis (0.04 mg/kg/hr, IQR 0.03-0.05 mg/kg/hr, p=0.0001). Bivalirudin doses correlated with Clcr (Spearman r = 0.58, p
CONCLUSION: Bivalirudin dosing requirements increased with increasing Clcr values. The high degree of variability suggests that dosing in individual patients will require careful titration to achieve adequate anticoagulation.
Runyan, Courtney L; Cabral, Katherine P; Riker, Richard R; Redding, David; May, Teresa; Seder, David B; Savic, Marizela; Hedlund, Jacqueline; Abramson, Stuart; and Fraser, Gilles L, "Correlation of bivalirudin dose with creatinine clearance during treatment of heparin-induced thrombocytopenia." (2011). Maine Medical Center. 2061.